Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

ATG or Post-Transplant Cyclophosphamide to Prevent GVHD in Matched Unrelated Stem Cell Transplantation?

[Leukemia] Investigators analyzed outcomes of abbit anti-thymocyte globulin vs. post-transplantation Cyclophosphamide prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood allogeneic stem cell transplantations from 10/10 antigen-matched unrelated donors between January 2018 and June 2021 in the EBMT database.

Induction of Immortal-Like and Functional CAR T Cells by Defined Factors

[Journal Of Experimental Medicine] Scientists demonstrated the induction of CAR T cells into an immortal-like and functional state, termed TIF. The induction of CARTIF cells depended on the repression of two factors, BCOR and ZC3H12A, and required antigen or CAR tonic signaling.

pO2 Reporter Composite Hydrogel Macroencapsulation Devices for Magnetic Resonance Imaging Oxygen Quantification

[Journal Of Biomedical Materials Research Part A] Scientists engineered pO2 reporter composite hydrogels to enable spatiotemporal measurement of oxygen tension within macroencapsulation devices using the proton Imaging of siloxanes to map tissue oxygenation levels magnetic resonance imaging approach.

DNAJB1-PRKACA Fusion Neoantigens Elicit Rare Endogenous T Cell Responses That Potentiate Cell Therapy for Fibrolamellar Carcinoma

[Cell Reports Medicine] Scientists defined endogenous CD8 T cell responses to a conserved DNAJB1-PRKACA gene fusion in fibrolamellar carcinoma patients and evaluate fusion-specific T cell receptors for use in cellular immunotherapies.

CAR’TCR-T Cells Co-Expressing CD33-CAR and dNPM1-TCR as Superior Dual-Targeting Approach for AML Treatment

[Molecular Therapy Oncology] CAR’TCR-T cells, co-expressing a CD33-CAR and a transgenic dNPM1-TCR, revealed increased and prolonged anti-tumor activity in vitro, particularly in case of low target antigen expression.

Enhanced Bacterial Cancer Therapy Delivering Therapeutic RNA Interference of C-Myc

[Cell & Bioscience] The attenuated tumour targeting Salmonella typhimurium SL7207 strain was modified to carry chromosomally integrated shRNA expression cassettes at the xylA locus.

Engineering Pre-Vascularized 3D Tissue and Rapid Vascular Integration with Host Blood Vessels via Co-Cultured Spheroids-Laden Hydrogel

[Biofabrication] Human adipose-derived stem cells and human umbilical vein cells were prepared as spheroids, which were encapsulated in gelatin methacryloyl hydrogels to fabricate a 3D pre-vascularized tissue.

Optimization of RNAi Efficiency in PVD Neuron of C. elegans

[PLOS One] In order to optimize the RNAi conditions for PVD neuron, scientists fed the worm strains with E. coli HT115 bacteria expressing dsRNA against mec-3, hpo-30, and tiam-1, whose loss of function were known to show dendrite morphology defects in PVD neuron.

Locally Directed Recombinant Adeno-Associated Virus–Mediated IGF-1 Gene Therapy Enhances Osteochondral Repair and Counteracts Early Osteoarthritis In Vivo

[American Journal Of Sports Medicine] Overexpression of insulin-like growth factor 1 (IGF-1) via recombinant adeno-associated viral vectors would improve osteochondral repair and reduce parameters of early perifocal osteoarthrisis in sheep after six months in vivo.

Nanomaterials Boost CAR-T Therapy for Solid Tumors

[Advanced Healthcare Materials] Researchers evaluated the use of various nanomaterials in the production of CAR-T cells, genetic modification, and in vivo delivery.

Cutting-Edge CAR-T Cancer Therapy Is Now Made in India — at One-Tenth the Cost

[Nature News] A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as CAR T-cell therapy that was pioneered in the United States. A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000.

FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma

[BioSpace] The risks of early death in the trials of Johnson & Johnson and Legend Biotech’s Carvykti and Bristol Myers Squibb and 2seventyBio’s Abcema were not a significant concern for the FDA’s Oncologic Drugs Advisory Committee, which voted 11-0 and 8-3 respectively to support the approvals of the CAR-T therapies as earlier lines of treatment for multiple myeloma.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

spot_img